Zidovudine- versus Tenofovir-Based Antiretroviral Therapy for the Initial Treatment of HIV Infection in the Ethnic Minority Region of Liangshan Prefecture, Sichuan Province, China

Cedric P. Cheung, Wen Hong Lai, Jonathan Shuter

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Tenofovir (TDF)-based highly active antiretroviral therapy (HAART), as recommended by the World Health Organization guidelines for HIV-naive patients, has been limited in resource-constrained settings. The aim of this study was to evaluate the effectiveness of zidovudine-(ZDV) versus TDF-based HAART in the Yi minority region of Sichuan Province, China at a single HIV treatment center. Methods: The primary end point was the attainment of an HIV viral load <50 copies/mL. Secondary end points included change in CD4 level, adverse reactions, mortality, and sustained virologic suppression. Results: Of the 361 total participants, recipients of TDF-based HAART were more likely to achieve viral load <50 copies/mL (60% versus 46%, odds ratio [OR] = 1.7, P =.016) as well as sustained virologic suppression (61% versus 28%, OR = 3.4, P =.001). Tenofovir (adjusted odds ratio [ORadj] = 1.71, P =.025) and female sex (ORadj = 1.93, P =.003) were identified as independent predictors of achieving HIV viral load <50 copies/mL in the multivariate logistic regression analysis. Conclusion: Among Chinese Yi minority HIV-infected participants, TDF-based HAART was superior to ZDV-based HAART for initial treatment of HIV infection, suggesting TDF-based HAART should be the regimen of choice in China.

Original languageEnglish (US)
Pages (from-to)189-193
Number of pages5
JournalJournal of the International Association of Providers of AIDS Care
Volume16
Issue number2
DOIs
StatePublished - Mar 1 2017

Fingerprint

Tenofovir
Zidovudine
Highly Active Antiretroviral Therapy
HIV Infections
China
HIV
Viral Load
Odds Ratio
Therapeutics
Logistic Models
Regression Analysis
Guidelines

Keywords

  • HAART
  • HIV
  • HIV viral load
  • tenofovir
  • zidovudine

ASJC Scopus subject areas

  • Immunology
  • Dermatology
  • Infectious Diseases

Cite this

@article{1a6cbeb7396740b1bd6df722e0713f53,
title = "Zidovudine- versus Tenofovir-Based Antiretroviral Therapy for the Initial Treatment of HIV Infection in the Ethnic Minority Region of Liangshan Prefecture, Sichuan Province, China",
abstract = "Background: Tenofovir (TDF)-based highly active antiretroviral therapy (HAART), as recommended by the World Health Organization guidelines for HIV-naive patients, has been limited in resource-constrained settings. The aim of this study was to evaluate the effectiveness of zidovudine-(ZDV) versus TDF-based HAART in the Yi minority region of Sichuan Province, China at a single HIV treatment center. Methods: The primary end point was the attainment of an HIV viral load <50 copies/mL. Secondary end points included change in CD4 level, adverse reactions, mortality, and sustained virologic suppression. Results: Of the 361 total participants, recipients of TDF-based HAART were more likely to achieve viral load <50 copies/mL (60{\%} versus 46{\%}, odds ratio [OR] = 1.7, P =.016) as well as sustained virologic suppression (61{\%} versus 28{\%}, OR = 3.4, P =.001). Tenofovir (adjusted odds ratio [ORadj] = 1.71, P =.025) and female sex (ORadj = 1.93, P =.003) were identified as independent predictors of achieving HIV viral load <50 copies/mL in the multivariate logistic regression analysis. Conclusion: Among Chinese Yi minority HIV-infected participants, TDF-based HAART was superior to ZDV-based HAART for initial treatment of HIV infection, suggesting TDF-based HAART should be the regimen of choice in China.",
keywords = "HAART, HIV, HIV viral load, tenofovir, zidovudine",
author = "Cheung, {Cedric P.} and Lai, {Wen Hong} and Jonathan Shuter",
year = "2017",
month = "3",
day = "1",
doi = "10.1177/2325957416686190",
language = "English (US)",
volume = "16",
pages = "189--193",
journal = "Journal of the International Association of Providers of AIDS Care",
issn = "2325-9574",
publisher = "SAGE Publications Inc.",
number = "2",

}

TY - JOUR

T1 - Zidovudine- versus Tenofovir-Based Antiretroviral Therapy for the Initial Treatment of HIV Infection in the Ethnic Minority Region of Liangshan Prefecture, Sichuan Province, China

AU - Cheung, Cedric P.

AU - Lai, Wen Hong

AU - Shuter, Jonathan

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Background: Tenofovir (TDF)-based highly active antiretroviral therapy (HAART), as recommended by the World Health Organization guidelines for HIV-naive patients, has been limited in resource-constrained settings. The aim of this study was to evaluate the effectiveness of zidovudine-(ZDV) versus TDF-based HAART in the Yi minority region of Sichuan Province, China at a single HIV treatment center. Methods: The primary end point was the attainment of an HIV viral load <50 copies/mL. Secondary end points included change in CD4 level, adverse reactions, mortality, and sustained virologic suppression. Results: Of the 361 total participants, recipients of TDF-based HAART were more likely to achieve viral load <50 copies/mL (60% versus 46%, odds ratio [OR] = 1.7, P =.016) as well as sustained virologic suppression (61% versus 28%, OR = 3.4, P =.001). Tenofovir (adjusted odds ratio [ORadj] = 1.71, P =.025) and female sex (ORadj = 1.93, P =.003) were identified as independent predictors of achieving HIV viral load <50 copies/mL in the multivariate logistic regression analysis. Conclusion: Among Chinese Yi minority HIV-infected participants, TDF-based HAART was superior to ZDV-based HAART for initial treatment of HIV infection, suggesting TDF-based HAART should be the regimen of choice in China.

AB - Background: Tenofovir (TDF)-based highly active antiretroviral therapy (HAART), as recommended by the World Health Organization guidelines for HIV-naive patients, has been limited in resource-constrained settings. The aim of this study was to evaluate the effectiveness of zidovudine-(ZDV) versus TDF-based HAART in the Yi minority region of Sichuan Province, China at a single HIV treatment center. Methods: The primary end point was the attainment of an HIV viral load <50 copies/mL. Secondary end points included change in CD4 level, adverse reactions, mortality, and sustained virologic suppression. Results: Of the 361 total participants, recipients of TDF-based HAART were more likely to achieve viral load <50 copies/mL (60% versus 46%, odds ratio [OR] = 1.7, P =.016) as well as sustained virologic suppression (61% versus 28%, OR = 3.4, P =.001). Tenofovir (adjusted odds ratio [ORadj] = 1.71, P =.025) and female sex (ORadj = 1.93, P =.003) were identified as independent predictors of achieving HIV viral load <50 copies/mL in the multivariate logistic regression analysis. Conclusion: Among Chinese Yi minority HIV-infected participants, TDF-based HAART was superior to ZDV-based HAART for initial treatment of HIV infection, suggesting TDF-based HAART should be the regimen of choice in China.

KW - HAART

KW - HIV

KW - HIV viral load

KW - tenofovir

KW - zidovudine

UR - http://www.scopus.com/inward/record.url?scp=85016094199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016094199&partnerID=8YFLogxK

U2 - 10.1177/2325957416686190

DO - 10.1177/2325957416686190

M3 - Article

C2 - 28043197

AN - SCOPUS:85016094199

VL - 16

SP - 189

EP - 193

JO - Journal of the International Association of Providers of AIDS Care

JF - Journal of the International Association of Providers of AIDS Care

SN - 2325-9574

IS - 2

ER -